Novartis receives FDA approval for expanded Zykadia use in first-line ALK-positive NSCLC
Novartis announced the FDA approved the expanded use of Zykadiaź (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. May 26, 2017